Publication:
Cell free DNA as a new prognostic biomarker for Covid-19, A prospective cohort study

Placeholder

School / College / Institute

Organizational Unit
Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Erdem, Hazal
Balkan,İlker İnanç
Karaali, Rıdvan
Ürkmez, Seval
Mete, Birgül
Aygün, Gökhan
Saltoğlu, Neşe
Tabak, Ömer Fehmi

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Predicting the need of hospitalization and intensive care in COVID-19 patients has been challenging with current diagnostic tests since the beginning of the pandemic. We aimed to test cell free DNA (cfDNA) as a novel biomarker for COVID-19 disease severity and mortality. cfDNA concentration was quantified by RT-PCR based test. One hundred and sixty-eight patients(85 outpatients, 61 inpatients,22 ICU) included the study. Mean initial plasma cfDNA levels were significantly different (p < 0.01) in outpatients (1.190,66 ng/ml), inpatients (8.258,10 ng/ml) and ICU patients (84.806,87 ng/ml). ROC analysis showed with 95 % specificity that patients with initial cfDNA concentrations >= 6.389 ng/ml need to be hospitalized and those >= 26.104 ng/ml require ICU referral. cfDNA concentration was correlated with neutrophil/lymphocyte ratio, lymphocyte level, CRP, AST, LDH, CK, fibrinogen, ferritin and D-dimer. Plasma cfDNA levels on admission, well correlating with disease severity and mortality in COVID-19 that found as a useful biomarker.

Source

Publisher

Elsevier Science Inc

Subject

Infectious diseases, Microbiology

Citation

Has Part

Source

Diagnostic Microbiology and Infectious Disease

Book Series Title

Edition

DOI

10.1016/j.diagmicrobio.2024.116367

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details